Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112789 | 0.84 | TSHR (0.63) | CETPL3MBTL1TSHR | |
| SCHEMBL4948490 | 0.83 | CYP3A4 (0.59) | CETPL3MBTL1TSHRALDH1A1CYP3A4 | |
| SCHEMBL7917113 | 0.83 | CYP3A4 (0.59) | CETPL3MBTL1TSHRALDH1A1CYP3A4 | |
| SCHEMBL2914825 | 0.81 | TSHR (0.71) | CETPL3MBTL1TSHRALDH1A1CYP3A4 | |
| SCHEMBL11145463 | 0.79 | CETP (0.57) | CETP | |
| SCHEMBL5615773 | 0.79 | CETP (0.53) | CETPL3MBTL1TSHRALDH1A1CYP3A4 | |
| SCHEMBL617402 | 0.78 | CYP3A4 (0.64) | TSHRCYP3A4 | |
| SCHEMBL11149582 | 0.78 | TSHR (0.62) | CETPL3MBTL1TSHRALDH1A1CYP3A4 | |
| SCHEMBL27937449 | 0.78 | CETP (0.56) | CETPL3MBTL1TSHRALDH1A1CYP3A4 | |
| SCHEMBL4948716 | 0.77 | CETP (0.63) | CETPTSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3984540-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | Aequor, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | CETP 2837/4885L3MBTL1 372/4885TSHR 1132/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | CETP 672/4885L3MBTL1 229/4885TSHR 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.